APU
IMUC

Alpine Partners USVI’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Alpine Partners USVI’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,311
Closed -$101K – 197
2013
Q2 		$101K Buy
+1,311
New +$126K 0.03% 166

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Alpine Partners USVI's IMUC Position: Q3 2013 in Review

Alpine Partners USVI sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2013, closing a stake of 1,311 shares — an estimated $101K sold.

Alpine Partners USVI first reported a position in IMUC in Q2 2013 and held it in 1 quarter. The position peaked at $101K in Q2 2013. 37 funds tracked by Wall St. Rank hold IMUC as of Q3 2013.

  • Alpine Partners USVI reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2013 after selling out during the quarter.
  • Alpine Partners USVI sold 1,311 ImmunoCellular Therapeutics, Ltd. shares in Q3 2013, an estimated $101K.
  • Alpine Partners USVI first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 1 quarter.
  • Alpine Partners USVI's ImmunoCellular Therapeutics, Ltd. position peaked at $101K in Q2 2013.
  • 37 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2013.

Based on Alpine Partners USVI's 13F filing for Q3 2013, filed 14 Nov 2013.